Novo Nordisk’s collaboration with artificial intelligence startup Valo Health has focused on developing new drugs for cardiovascular disease. The pharmaceutical giant likes what it’s seen so ...
Jan 8 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for ...
During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...
Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, ty ...
Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.
8 January 2025 – Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes ...
Novo Nordisk NOVO.B2.14%increase; green up pointing triangle expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback